$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Medical News
Medical News
Where can Serpatinib be sold in China?
2025-10-19 11:44:20
Check Details
Serpatinib Drug Instructions
2025-10-19 11:44:20
Check Details
Serpatinib storage conditions
2025-10-19 11:44:20
Check Details
Early diagnosis and detection improves survival outcomes in EGFR+ non-small cell lung cancer - Kanghule
2025-10-19 11:44:20
Check Details
New targeted drug D-0316 has clinically significant efficacy in treating T790M+ and EGFR+ non-small cell lung cancer
2025-10-19 11:44:20
Check Details
New dosing regimen of pozitinib has better efficacy and tolerability in the treatment of non-small cell lung cancer_ Kanghule
2025-10-19 11:44:20
Check Details
New hope for c-Met+ non-small cell lung cancer, Telisotuzumab Vedotin is coming!
2025-10-19 11:44:20
Check Details
What patients with lung cancer need to know about using afatinib_Cortex
2025-10-19 11:44:20
Check Details
Afatinib has significant effect in the treatment of advanced lung squamous cell carcinoma_ Kanghule
2025-10-19 11:44:20
Check Details
The occurrence and treatment options of lung squamous cell carcinoma
2025-10-19 11:44:20
Check Details
The therapeutic effect of taking the targeted drug crizotinib in late-stage lung cancer
2025-10-19 11:44:20
Check Details
How effective is afatinib in the treatment of advanced lung squamous cell carcinoma?
2025-10-19 11:44:20
Check Details
1
2
...
9906
9907
9908
9909
9910
9911
9912
...
10204
10205
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Precision Breakthrough: Inavolisib Redefines Survival in PIK3CA-Mutant Breast Cancer
2
Romiplostim vs. Eltrombopag: ITP Treatment Dosing Differences and Precision Selection
3
Asciminib: Mechanism and Clinical Value of the First ABL Allosteric Inhibitor
4
Is Eplerenone Suitable for Long-Term Use?
5
Does Ixazomib (Ninlaro) Require Long-Term Use to Be Effective?
6
Optimal Regorafenib (Stivarga) Administration Guide: Low-Fat Diet, Fixed Timing, and Dose Escalation Strategies
7
What is the effectiveness of the new weapon for myeloma patients: cetuximab? Listen to what the user has to say
8
Guidelines for the timing, method, and precautions of taking Erlotinib (Trokai).
9
What diseases can Upatinib be used for? Which patients are suitable for use?
10
The efficacy of Eltrombopag
11
User Agreement
12
Herceptin Hylecta treats HER2-positive breast cancer and only needs to be injected subcutaneously and only used once every three weeks